Over the past few years, cancer research has increasingly shifted its focus toward the immune system. New studies on cancer vaccines are making headlines daily, driven by the hope of training the immune system to recognize and attack tumors.
Vaccines were originally designed to teach the immune system to recognize and fight off foreign invaders like viruses or bacteria, organisms that clearly don’t belong in the body. Cancer vaccines, on the other hand, flip that logic.
Instead of targeting something foreign, they operate under the assumption that your immune system is failing to recognize your own mutated, damaged cells as a threat. The goal is to wake up or redirect your immune system to identify those sick cells as dangerous and destroy them, something it normally avoids doing, since cancer originates from your own tissues.
Traditional vaccines amplify what your immune system already wants to do—fight invaders.
Cancer vaccines try to override immune tolerance and teach the immune system to see your own damaged cells as a threat.
Therapeutic (treatment) vaccines are designed to treat cancer (rather than preventing cancer) by stimulating the immune system to attack cancer cells. These are complex and still mostly in research or early use. Some of these include:
mRNA vaccines
- Deliver mRNA instructions to make tumor-specific proteins (neoantigens)
- Cells produce these proteins which the immune system recognizes as abnormal
- Activates CD8+ T cells to hunt and kill cancer cells with those same proteins
Dendritic cell vaccines
- Patient’s dendritic cells are collected through blood and are exposed to tumor-specific antigens in the lab, essentially “training” them to recognize the cancer
- Cells are then reinfused back into the patient, where they help activate T cells to launch a targeted immune response
- Highly personalized and time-intensive; an example is Provenge (sipuleucel-T) used for prostate cancer
Peptide/protein vaccines
- Contain lab-made protein fragments that mimic cancer antigens
- Immune cells present them to T cells to train recognition
- Simple and widely used, but often need adjuvants for a strong response
Viral vector vaccines
- Use viruses to deliver cancer antigen genes into cells
- Triggers a strong immune response by mimicking infection
- Helps immune system recognize and destroy cancer cells
But the cancer vaccine model rests on a narrow understanding of what cancer is and what drives it in the first place.
It assumes cancer is purely the result of mutated cells that need to be eliminated, as if the problem is just a glitch in surveillance. But cancer isn’t just a collection of mutated cells. It reflects a breakdown in the body’s internal environment: inflammation, immune dysfunction, mitochondrial stress, hormonal imbalances, toxicity, nutrient depletion, and more.
There is no magic bullet that can unwind this complexity. Injecting a sequence of code, no matter how clever, doesn’t address why the terrain allowed cancer to grow in the first place. It doesn’t restore balance, rebuild the immune system, or correct the deeper conditions that allowed those cells to become cancerous.
A treatment that targets the end product (the tumor) but ignores the root cause may slow things down, but it rarely leads to healing or a “cure.”
The core assumption behind cancer vaccines is that cancer cells carry DNA mutations that lead to the production of abnormal proteins. Cancer vaccines are designed around these mutations, but what they actually target are the mutated proteins produced because it’s these protein fragments, not the DNA itself, that the immune system can recognize and attack.
But, that’s not always the case. Some cancer cells don’t have obvious mutations at all, and some healthy cells do—yet they aren’t cancerous. This is part of what has stumped cancer researchers for decades: we still haven’t identified a consistent genetic target that explains cancer across the board. It’s why attempts to “cure” cancer by targeting individual genes or mutations have repeatedly fallen short.
It also assumes that immune dysfunction is the primary cause of cancer. That the immune system simply failed to recognize and destroy a dangerous cell. But what if the cell isn’t “dangerous” in the way we think?
The one thing we consistently know about cancer cells is that they produce energy differently than healthy cells. Rather than relying on oxygen to produce energy in the mitochondria (oxidative phosphorylation), cancer cells shift toward glycolysis, even when oxygen is available. That’s not a mutation, it’s an adaptation, and it’s seen in wound healing, embryonic development, and cells under severe stress.
So maybe the immune system doesn’t “see” the cancer cell as a threat because it’s not inherently malfunctioning, it’s simply adapting and trying to help you cope with an overwhelmed internal environment. In that light, the idea that the immune system must be trained to attack it, especially aggressively, starts to feel more like a forced override than a true fix.
And this comes with risk. Over activating the immune system can have real downstream effects: chronic inflammation, autoimmunity, tissue damage, and long-term immune exhaustion. If we don’t resolve the conditions that contributed to the cancer’s development in the first place, then removing the tumor may resolve the immediate problem, but it does little to prevent another from forming later on.
Studies have shown that when the immune system is overstimulated, it can begin attacking healthy tissues, not just cancer. These toxic effects can impact almost any organ, but most commonly the thyroid, colon, lungs, and occasionally more severe damage to the liver, heart, or brain. Many patients end up needing to stop treatment or take immunosuppressants to control the damage. Cancer vaccines operate through a similar mechanism which raises similar concerns.
Unlike personalized nutrition, natural therapies, drug repurposing, or long-term lifestyle-based care, vaccines can be patented. Add to that a narrative of “training your body to heal itself,” and you have the perfect storm of innovation, investment, and marketing. Whether or not the science is settled, the business case is already compelling.
The cancer immunotherapy market is projected to grow from $126 billion in 2023 to over $296 billion by 2033.
Right now, headlines are overwhelmingly in favor of cancer vaccines, painting them as the next major breakthrough in oncology.
But many of these vaccines are still in early-stage trials, have small sample sizes, short follow-up periods, and highly selected patient groups. I think it’s good to be curious and critical, and make sure these therapies are thoroughly tested before being widely adopted or celebrated as a cure. Science moves forward best with hope and healthy skepticism. Science moves forward best with hope and healthy skepticism.